BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $31.00 Average Target Price from Analysts

by · The Cerbat Gem

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $32.00.

A number of research firms have recently issued reports on BLFS. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of BioLife Solutions in a report on Monday, December 29th. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Finally, UBS Group restated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th.

Check Out Our Latest Stock Report on BioLife Solutions

Insider Buying and Selling

In related news, Director Joydeep Goswami sold 1,666 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $28.99, for a total value of $48,297.34. Following the completion of the transaction, the director owned 44,986 shares of the company’s stock, valued at approximately $1,304,144.14. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Greef Roderick De sold 37,795 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total value of $1,031,803.50. Following the sale, the chief executive officer owned 489,998 shares in the company, valued at $13,376,945.40. This represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 937,664 shares of company stock worth $26,311,309 over the last quarter. Company insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the company. Amalgamated Bank lifted its holdings in shares of BioLife Solutions by 3.5% in the 3rd quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the period. Louisiana State Employees Retirement System lifted its stake in BioLife Solutions by 2.9% in the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after buying an additional 500 shares during the last quarter. Isthmus Partners LLC lifted its stake in BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after buying an additional 509 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of BioLife Solutions by 2.7% during the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after acquiring an additional 555 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Trading Up 5.9%

Shares of NASDAQ BLFS opened at $25.31 on Friday. BioLife Solutions has a 12-month low of $19.10 and a 12-month high of $29.62. The company has a market cap of $1.22 billion, a P/E ratio of -361.52 and a beta of 1.93. The stock has a fifty day moving average price of $25.59 and a 200 day moving average price of $24.77.

About BioLife Solutions

(Get Free Report)

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.

Featured Articles